daunorubicin has been researched along with 1-methyl-3-isobutylxanthine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruserud, O; Døskeland, SO; Gausdal, G; Gjertsen, BT; Havemann, U; Herfindal, L; Kleppe, R; Lanotte, M; McCormack, E; Nguyen, E; Pendino, F; Rouhee, N; Schwede, F; Ségal-Bendirdjian, E; Skavland, J; Wergeland, A | 1 |
1 other study(ies) available for daunorubicin and 1-methyl-3-isobutylxanthine
| Article | Year |
|---|---|
Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Antibiotics, Antineoplastic; Apoptosis; bcl-Associated Death Protein; Cell Line, Tumor; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinase Type I; Cyclic AMP-Dependent Protein Kinase Type II; Daunorubicin; Dinoprostone; Disease Progression; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; RNA Interference; RNA, Small Interfering; Theophylline; Transplantation, Heterologous; Tretinoin | 2013 |